Full history for every metric is available with a Kvantra account
Oventus Medical Limited (OVN.AX)
Key financial summary
Financials in AUD| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | AUD m | - | 0 | 0 | 0 | 0 | 1 | 1 |
| Operating profit | AUD m | -10 | -10 | |||||
| Net profit | AUD m | - | -7 | -6 | -8 | -10 | -10 | -10 |
| EPS reported | AUD | -0.06 | -0.06 | |||||
| Operating cashflow per share | AUD | -0.04 | -0.04 | |||||
| Capex per share | AUD | 0.01 | 0.01 | |||||
| FCF per share | AUD | -0.05 | -0.05 | |||||
| Free cash flow | AUD m | -8 | -8 | |||||
| Net debt | AUD m | -9 | -9 | |||||
| Book value equity | AUD m | 13 | 13 | |||||
| Book value per share | AUD | 0.08 | 0.08 | |||||
| Number of shares | m | 161.92 | 161.92 | |||||
| DPS (TTM paid) | AUD | 0.00 | 0.00 |
Financial summary
Financials in AUD| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.22 | 0.38 | |||||
| P/S LTM | x | 14.12 | 4.44 | |||||
| P/FCF LTM | x | -1.82 | -0.57 | |||||
| EV/EBITDA LTM | x | -0.80 | 0.51 | |||||
| EV/Sales LTM | x | 6.21 | -3.97 | |||||
| Earnings Yield LTM | % | -64.93% | -308.40% | |||||
| FCF Yield | % | -54.81% | -174.41% | |||||
| Quality | ||||||||
| ROE | % | -79.15% | -80.43% | |||||
| ROIC | % | -74.27% | -74.27% | |||||
| Operating margin | % | -899.55% | -899.55% | |||||
| Gross margin | % | 36.86% | 36.86% | |||||
| FCF/Sales | % | -773.88% | -773.88% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +159.85% | +159.85% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -15.65 | -15.65 | |||||
| Net Debt/EBITDA | x | 1.02 | 1.02 | |||||
| EBIT/Net interest | x | -319.33 | -319.33 | |||||
| Net debt/market cap | % | -56.02% | -189.40% | |||||
| Net debt/Equity | x | -0.68 | -0.73 | |||||
| Gross debt/equity | x | 0.04 | 0.04 | |||||
Company overview
Oventus Medical Limited is a medical device enterprise focused on the creation and commercialization of oral appliances designed to alleviate obstructive sleep apnea (OSA) and snoring. The company distributes its solutions across Australia, Canada, and the United States. Key offerings include the O2Vent Optima, a custom 3D-printed nylon oral appliance developed for OSA patients, and ExVent, a valve accessory specifically designed to fit into the O2Vent Optima's airway. Established in 2015, the firm's main office is located in Indooroopilly, Australia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Oventus Medical Limited (OVN.AX)
Oventus Medical Limited is a medical device enterprise focused on the creation and commercialization of oral appliances designed to alleviate obstructive sleep apnea (OSA) and snoring. The company distributes its solutions across Australia, Canada, and the United States. Key offerings include the O2Vent Optima, a custom 3D-printed nylon oral appliance developed for OSA patients, and ExVent, a valve accessory specifically designed to fit into the O2Vent Optima's airway. Established in 2015, the firm's main office is located in Indooroopilly, Australia.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free